# Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine

> **NCT05857566** · PHASE1 · COMPLETED · sponsor: **Response Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Drug-induced Weight Gain

## Interventions

- **DRUG:** RDX-002

## Key facts

- **NCT ID:** NCT05857566
- **Lead sponsor:** Response Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-16
- **Primary completion:** 2023-07-13
- **Final completion:** 2023-09-13
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05857566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05857566, "Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05857566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*